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Abstract
Two paternally-inherited missense variants in CACNA1H were identified and characterized in a 6-year-old child with
generalized epilepsy. Febrile and unprovoked seizures were present in this child. Both variants were expressed in cis or
isolation using human recombinant Cav3.2 calcium channels in tsA-201 cells. Whole-cell patch-clamp recordings
indicated that one variant (c.3844C > T; p.R1282W) caused a significant increase in current density consistent with a
pathogenic gain-of-function phenotype; while the other cis-related variant (c.5294C > T; p.A1765V) had a benign profile.
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Introduction
CACNA1H encodes the α1 pore-forming subunit of the
low-voltage activated (LVA) Cav3.2 T-type calcium
channel. This channel is known to control neuronal ex-
citability, plays a role in generating rebound burst-firing
in thalamic reticular neurons and may contribute to
neurotransmitter release at certain CNS synapses [1–3].
A number of missense mutations have been identified in
CACNA1H in subjects with different types of generalized
epilepsy that include: febrile, myoclonic, temporal lobe,
and childhood and juvenile absence epilepsies [4–7].
Pathogenic variants have been identified along the entire
length of the Cav3.2 channel sequence, with the most
concentrated number of variants being within the intra-
cellular region connecting the first and second trans-
membrane domain of the channel (see Fig. 1a). Several
of these variants have been examined physiologically
when expressed in heterologous systems. These studies re-
port that a subset of these epilepsy-associated variants
caused gain-of-function mutations, either through in-
creased whole-cell current amplitude or via alterations in
the inactivation properties of the channels [5, 8–11]. Al-
though several reported variants failed to alter channel
properties, it is important to remember that dysfunction
may be related to the expression patterns of specific splice
isoforms. For example, the Genetic Absence Epilepsy Rats
from Strasbourg (GAERS) model has altered physi-
ology when these channels contain exon 25, a splice
variant transcript that is highly expressed in the thal-
amus [12]. Moreover, it is possible that mutations may
compromise interactions with binding partners such
as HCN channels [13] without affecting channel func-
tion per se. Altogether, there is considerable evidence
linking Cav3.2 mutations to epilepsy in rodent models
and humans.
We report two novel missense variants (p.R1282W and
p.A1765V) in the CACNA1H gene that encodes the Cav3.2
channel in a 6-year-old girl with multifocal and primary
generalized epilepsy. Electrophysiological evaluations of
these two variants in cis and in isolation indicate that the
CACNA1H-R1282W mutant mediates gain-of-function
properties in Cav3.2 channels.
Materials and methods
Genetic analysis
Genomic DNA was extracted from blood from the
subject and her father. Variants were identified with the
Clinical Management Panel for Neurodevelopment Dis-
orders (Courtagen, Woburn, MA).
Molecular cloning and electrophysiology
QuikChange site-directed mutagenesis kit (Agilent Tech-
nologies) was used to insert the two variants in isolation
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and in cis into the wild-type (WT) human Cav3.2 α1
subunit gene (GenBank: NM_021098.2). The pcDNA3.1
vector was used for expression of the wild-type protein
and three types of variants (p.R1282W alone, p.A1765V
alone, and both together in cis) in tsA-201 cells.
Cell culture, transfection, and electrophysiology
Human embryonic kidney tsA-201 cells were cultured
and transiently transfected using the calcium phosphate
method. Three micrograms of each Cav3.2 cDNA and
0.5 μg of eGFP were transfected and cells were grown
for 72 h at 30 °C (to prevent cell overgrowth) before
experiments were carried out. Whole cell patch clamp
recordings were performed using an Axopatch 200B
amplifier linked to a computer with pCLAMP 9.2 soft-
ware. The current-voltage relationships were acquired
and fitted with a Boltzmann equation as described
previously [14].
Whole cell patch clamp recordings were performed at
room temperature (22–24 °C) using an Axopatch 200B
amplifier linked to a computer with pCLAMP 9.2 soft-
ware. The external solution contained (in mM): 10 BaCl2,
125 CsCl, 1 MgCl2, 10 HEPES and 10 Glucose, pH
adjusted to 7.4 with CsOH. The internal pipette solution
contained (in mM): 130 CsCl, 2.5 MgCl2, 10 HEPES, 5
EGTA, 3 ATP 0.5 GTP, pH 7.4. The current-voltage rela-
tionships were acquired and fitted with a Boltzmann equa-
tion as described previously [14]. Steady-state inactivation
was acquired by applying 1 s conditioning pulses from −
100 to − 30mV in 10mV increments followed by a 25ms
test pulse to − 20mV. Currents were normalized to the
maximum current and fitted with a Boltzmann equation.
Recovery from inactivation was evaluated by applying two
test pulses (P1 and P2) to − 20mV separated by a varying
interval ranging from 10ms to 2 s. P2/P1 was plotted as a
function of time. Data were analyzed using Clampfit 10.3
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Fig. 1 Biophysical effects of Cav3.2 mutations. a Schematic representation of the Cav3.2 channel showing the approximate location of the
R1282W and A1765V mutations. b Representative Ba2+ current traces recorded from WT, R1282W and A1765V channels. c Average current
densities (pA/pF) as a function of voltage for WT, R1282W and A1765V channels, showing a 2-fold increase in current densities of the R1282W
mutant. d Steady-state inactivation curves for WT, R1282W and A1765V channels. e Representative western blot of surface biotinylation of WT
and R1282W channels showing no difference in surface expression. Beads control represents non-biotinylated cells. Mock represents mock
transfected cells. The graph shows quantified Cav3.2 integrated density normalized by Na+K+ATPase signal
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software (Molecular Devices) and fit using GraphPad
Prism 6. Averaged data are plotted as mean ± SE and
statistical analysis was performed using Student’s t tests,
where p ≤ 0.05 was considered significant.
Results
Subject
The subject is a six-year-old female with primary gener-
alized epilepsy and a paternal history of childhood
absence epilepsy that resolved “within a few years”. The
child was born at 33.5 weeks gestation via emergent
cesarean section due to maternal pre-eclampsia and had
an uncomplicated three-week NICU stay prior to dis-
charge. Her development was normal, with her first
words at 10 months and ambulation at 14 months. Her
physical and neurological examinations have consistently
been within normal limits.
Her first convulsive seizure was at 14 months in the
setting of a febrile illness. She had two more febrile con-
vulsive episodes within the next month that were noted
to start with right-sided twitching. She had ten add-
itional convulsions in the setting of fever during the fol-
lowing year, most of which were prolonged and required
abortive benzodiazepine treatment. She had her first un-
provoked generalized tonic-clonic seizure at 2 years of
age. The child was then started on Leviteracetam and
did well for some time, but developed aggressive behav-
ior and was switched to lamotrigine. She has had no fur-
ther seizures since starting anti-seizure medications,
except in the setting of febrile illnesses.
Neurodiagnostic testing
Electroencephalogram (EEG) and brain MRI were nor-
mal after her first seizures at 17 months. A subsequent
EEG after her first unprovoked seizure at 2 years had
bilateral multi-focal discharges (right greater than left)
arising from the frontal central and anterior temporal re-
gions, along with generalized spike and multispike and
slow wave discharges of 3–4 Hz with bifrontal predom-
inance. At 6 years, another EEG showed frequent gener-
alized 2–2.5 Hz spike and wave discharges with bifrontal
predominance lasting up to 10 s. This EEG was also
notable for one episode of behavioral arrest lasting 5 s
during hyperventilation that was associated with a burst of
2.5 Hz generalized spike and wave discharges (consistent
with an absence seizure).
Genetic testing
Genetic sequencing revealed two paternally-inherited
missense variants in the CACNA1H gene (c.3844C > T,
p.R1282W and c.5294C > T, p.A1765V) in the same al-
lele. The variant A1765V, located in the transmembrane
region S5 of domain IV (Fig. 1a), had been previously
observed in 4 out of 24,702 individuals in the ExAC
database (http://exac.broadinstitute.org); while the R1282W
variant was located in the cytoplasmic II-III loop (Fig. 1a)
and was not found within this database.
Electrophysiology
Whole-cell patch clamp recordings of Cav3.2 channels
containing the variants R1282W and A1765V were com-
pared to wild-type channels (WT). Representative current
traces for WT, R1282W and A1765V channels are shown
in Fig. 1b. The peak current density recorded from cells
expressing R1282W was significantly increased (p < 0.05,
One Way ANOVA followed by Tukey’s multiple compari-
sons test) when compared to WT (Fig. 1c, Table 1). This
effect was not due to a change in cell surface expression of
the channel as determined by surface biotinylation experi-
ments (Fig. 1e). Neither of the mutations caused a change
in steady-state inactivation and recovery from inactivation
properties of the channel compared to WT, nor did they
affect the half-activation potential (Fig. 1d, Table 1).
The transmembrane A1765V mutant in isolation
was similar to WT channels in all of the parameters
tested (Fig. 1b-d, Table 1). We also examined possible
synergistic effects of the two mutations when placed
within the same allele. These experiments showed that
A1765V produced no additive effects on current dens-
ity and activation kinetics to those observed with
R1282W alone (Fig. 2a-b); however, the mean half-in-
activation voltage was slightly shifted to more a positive
potential (p < 0.0001, Student’s t-test) (Fig. 2c-d). This in
turn results in an increase in the size of the normalized
window current by 15%, overall consistent with a gain of
function beyond the increase in whole cell current density.
The mechanistic underpinnings of this additive effect on
inactivation are unclear.
Discussion
CACNA1H pathogenic variants have been associated with
multiple disorders, including aldosteronism, autism, amyo-
trophic lateral sclerosis, but is predominantly associated
Table 1 Summary of electrophysiological parameters of wild-type (WT), R1282W and A1765V channels expressed in tsA-201 cells
Peak current density (pA/pF) Gmax (nS) V1/2 act (mV) V1/2 inac (mV) τrecov (ms)
WT −34.39 ± 3.7 (17) 0.6 ± 0.06 (17) −40.94 ± 0.9 (17) −62.1 ± 0.9 (15) 239.4 ± 28.5 (14)
R1282W −69.8 ± 10.8 (26)* 1.1 ± 0.15 (26)* −43.5 ± 1.0 (26) −62.2 ± 0.8 (16) 287.1 ± 26.9 (9)
A1765V −35.7 ± 5.6 (12) 0.6 ± 0.09 (12) − 41.9 ± 0.9 (12) −62.3 ± 0.6 (17) 259.3 ± 25.4 (11)
Data are represented as mean ± SEM. Numbers in parentheses represent number of cells analyzed. *p < 0.05, One Way ANOVA followed by Tukey’s multiple
comparison test
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with epilepsy [15–17]. Here, we characterized the
functional effects of two missense variants identified
in the CACNA1H gene from a patient with epilepsy.
These variants were introduced into the Cav3.2 chan-
nel isoform that contains the exon 25, a subtype that
is highly expressed in the thalamus [12]. The A1765V
mutation alone had no effect on any of the parameters
tested and was predicted to be benign by SIFT soft-
ware analysis (http://sift.bii.a-star.edu.sg). These data
and its frequency in the population indicate this may
indeed likely be a benign variant. It is important to
note that some point mutations found in calcium
channels can also behave differently when introduced
into different isoforms of the channel [12], when channels
are expressed in a different cellular milieu [18], or
recorded in different external solutions [14]. Moreover, it
has been shown that T-type channels gate much faster at
physiological temperatures [19], and it is possible that mu-
tations may affect channel behavior differently at 37 °C
compared to room temperature where we conducted our
analysis. In contrast, the R1282W variant was a novel vari-
ant that SIFT analysis predicted to potentially alter protein
function. When compared to WT Cav3.2 channels, the
R1282W-variant was shown to cause a significant 2-fold
increase in whole cell current density (Fig. 1b-c, Table 1),
consistent with a gain-of-function mutation. Given that
cell surface expression was unaltered for this variant, these
data indicate that the mutation may have either increased
the single channel conductance or the maximum open
probability at the plateau of the activation curve.
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Fig. 2 Biophysical analysis of variants R1282W and A1765V in cis. a Average current densities (pA/pF) as a function of voltage for WT and
R1282W-A1765V channels, showing an increase in current density for R1282W-A1765V. Numbers in parentheses reflect numbesr of cells. b Mean
half-voltage of activation values for R1282W-A1765V compared to WT channels. c Steady-state of inactivation curves for WT and R1282W-A1765V
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T-type channel dysfunction fits well with a pathogenic
model of this disorder as they are important for the
thalamocortical network, where they contribute to gen-
eration of bursts of action potentials and network oscil-
lations [2]. Therefore, an increase in T-type channel
activity can shift the balance between excitatory and in-
hibitory neurotransmission and increase seizure suscep-
tibility. This is also supported by genetic rodent models
of epilepsy, such as GAERS and the Wistar Albino Glaxo
Rats from Rijswijk (WAG/Rij), which exhibit an increase
in T-type channel function in nRT neurons [20, 21].
However, although certain mutations in Cav3.2 channels
have been previously associated with an increased inci-
dence of febrile seizures [5], this may not necessarily in-
volve a dysfunction of the thalamocortical network.
Importantly, T-type calcium channels are prominently
expressed in other brain structures that are linked to fe-
brile seizure disorders, including the hippocampus, and
have been shown to play an important role in generating
seizure activity in this brain region [22–26].
The impact of variants identified in patients with dif-
ferent disorders can be very difficult to predict without
the functional analysis of the affected proteins. The in-
crease in availability of high through-put sequencing
data have provided numerous examples where functional
analysis is important to confirm pathogenicity in rare
disorders in which some potentially pathogenic variants
are found to be quite common in the general unaffected
population and therefore likely benign [27]. This be-
comes an even greater challenge when studying complex
diseases such as epilepsy, which may have polygenic
and/or multifactorial origins. Many variants identified in
the CACNA1H gene have shown little physiological al-
terations when tested in vitro and are not considered
sufficiently pathogenic to cause epilepsies on their own
[5, 9]; however, they are believed to act in combination
with variants in other susceptibility genes and/or envir-
onmental factors to raise the level of neuronal excitabil-
ity and generate seizures [28]. In addition, it is possible
that even small changes in electrophysiological proper-
ties of Cav3.2 channels may affect downstream signaling
processes such as calcium-dependent gene transcription,
which in turn may lead to the dysregulation of pathways
that culminate in increased seizure susceptibility. In
summary, a functional analysis of these two cis-linked
variants revealed that only one of them caused a novel
pathogenic gain-of-function (R1282W) mutation in
CACNA1H, while the other variant seems likely benign.
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